Daniela Thommen

Immunotherapy has revolutionized cancer treatment and is now used for many cancer types. However, not all patients benefit yet from this therapy. As a tool to investigate the effects of immunotherapy outside of the patient, our group develops patient-derived organotypic tumor models. Using these models, we study how tumor immune composition and architecture influence immunotherapy responses and how distinct treatments can alter immune activity in a tumor.

Our ultimate goal is to contribute to the development of personalized immunotherapies by identifying new biomarkers or treatment strategies.